# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wall Street rallied to start the week, with small-cap stocks and regional banks rebounding sharply after last week's credit...
Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) from Hold to Hold.
U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher.
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial
Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from...